• Korro Bio reported preclinical results for subcutaneous KRRO-111, highlighting its potential to treat lung and liver manifestations of alpha-1 antitrypsin deficiency.
• Repeat-dose mouse studies achieved 96% SERPINA1 mRNA editing, with functional M-AAT comprising 93% of total circulating AAT.
• Total circulating AAT reached 172 μM at Day 57, about six times vehicle-control levels.
• In a separate mouse model, KRRO-111 reduced liver levels of pathogenic Z-AAT by 95% versus vehicle control at Day 57.
• A regulatory submission for KRRO-111 is expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220700PRIMZONEFULLFEED9850957) on October 22, 2026, and is solely responsible for the information contained therein.